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Objective: Diminish interleukin-1b (IL-1b) signaling in a model of primary osteoarthritis by RNA
interference-based transcript reduction or receptor blockade, and quantify changes incurred on tran-
script expression of additional mediators.
Methods: Knees of Hartley guinea pigs were collected at 120 and 180 days of age following injection with
viral vectors (N ¼ 4/treatment group/date) at 60 days. Two groups received either adeno-associated viral
serotype 5 vector containing a knockdown sequence (TV), or adenoviral vector encoding for IL-1 receptor
antagonist protein (Ad-IRAP); treatments were contrasted with opposite knees administered corre-
sponding vector controls. A third group evaluated TV relative to saline-only injected knees. Chondrop-
athy and immunohistochemistry ﬁndings were compared to untreated guinea pigs. Transcript expression
levels in cartilage were calculated using the comparative CT (2DDCT) method and analyzed by one-way
analysis of variance (ANOVA) with pairwise comparisons using Tukey 95% conﬁdence intervals.
Results: Vector transduction was conﬁrmed at both harvest dates. TV and Ad-IRAP, relative to vector
controls, signiﬁcantly decreased IL-1b. Inﬂammatory mediators [tumor necrosis factor-a (TNF-a), IL-8,
interferon-g (IFN-g)], and catabolic matrix metalloproteinase 13 (MMP13) were also decreased, while
anabolic transforming growth factor-b1 (TGF-b1) was increased. IL-1bwas also decreased by TV vs saline,
with a decrease in MMP13 and increase TGF-b1; TNF-a, IL-8, and IFN-g were transiently increased.
Conclusions: This work conﬁrmed that a reduction in IL-1b signaling was accomplished by either method,
resulting in decreased expression of three inﬂammatory mediators and one catabolic agent, and
increased expression of an anabolic molecule. Thus, evidence is provided that IL-1b serves a role in vivo
in spontaneous osteoarthritis and that these translational tools may provide beneﬁcial disease
modiﬁcation.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the leading cause of physical disability in
developed nations1. Unfortunately, multiple molecular and
biomechanical factors contribute to the pathogenesis of this
degenerative process and restorative treatment options continue to
be elusive2. Interleukin-1b (IL-1b), a pro-inﬂammatory cytokine
that stimulates joint tissue to produce several proteases involved in
cartilage degradation, is implicated as a principal instigator of OA3.
Inhibiting the biological activities of IL-1b through RNA interfer-
ence (RNAi) or receptor antagonismmay delineate the contributionA.L. Bertone, Department of
t, The Ohio State University,
-292-3526.
ertone).
s Research Society International. Pof its signaling pathway to disease and offers promise as a trans-
lational therapeutic strategy. Efforts to reduce or block the effective
concentration of IL-1b have been demonstrated using diacerein,
a compound that inhibits IL-1b production from synovium and
cartilage4e10, or IL-1 receptor antagonist protein (IRAP) in experi-
mental OA11e15. Although these studies suggest that IL-1b is a viable
target to modify development and succession of secondary joint
deterioration, the majority of human cases of OA are idiopathic16
and work is warranted to evaluate the deﬁnitive role of IL-1b in
the context of spontaneous disease3,17.
Recently, our laboratory provided a comprehensive immuno-
histochemical map describing the temporal expression and tissue
distribution of IL-1b through progression of OA in two strains of
guinea pigs with varying propensity for spontaneous knee joint
disease18. At 60 days of age, IL-1bwas detected in cartilage, menisci,
synovium, and subchondral bone in both strains. Persistentublished by Elsevier Ltd. All rights reserved.
Table I
A. Targeting knockdown and control shRNA sequences
Targeting
knockdown
IL-1b
sequence
GCCAGGATATAATTGACTTCACGAATGAAGTCAATTATATCCTGGC
Non-targeting
control
sequence
GGATATATCCCGAACTAGACACGAATGTCTAGTTCGGGATATATCC
B. Speciﬁc primers used for real-time qRT-PCR
Transcript of interest Primer sequences (50e30)
18S ribosomal RNA F: TGCATGGCCGTTCTTAGTTG
R: AGTTAGCATGCCAGAGTCTCGTT
GAPDH F: GTATCGTGGAAGGACTCATGACC
R: GTTGAAGTCACAGGACACAACCT
GFP F: CATGATATAGACGTTGTGGCTGTTG
R: AAGCTGACCCTGAAGTTCATCTGC
Fireﬂy luciferase* F: GCCTGAAGTCTCTGATTAAGT
R: ACACCTGCGTCGAAGT
CVM promoter F: GGTCTATATAAGCAGAGCTG
R: GTGGTATGGCTGATTATGATCAG
IL-1b F: ACGCCTGGTGTTGTCTGAC
R: GGGAACTGAGCGGATTC
IL-8 F: GGCAGCCTTCCTGCTCTCT
R: CAGCTCCGAGACCAACTTTGT
Human IRAPy F: TGGCTAACTAGAGAACCCACTGCT
R: TTCTGAAGGCTTGCATCTTGCTGG
Collagenase 3 (MMP13) F: TTCTGGCACATGCTTTTCCTC
R: GGTTGGGGTCTTCATCTCCTG
TGF-b1 F: CATCGATATGGAGCTGGTGAAG
R: GCCGTAATTTGGACAGGATCTG
TNF-a F: CCTACCTGCTTCTCACCCATACC
R: TTGATGGCAGAGAGAAGGTTGA
INF-g F: ATTTCGGTCAATGACGAGCAT
R: GTTTCCTCTGGTTCGGTGACA
* Fan X, Roy E, Zhu L, Murphy TC, Kozlowski M, Nanes MS, Rubin J. Nitric oxide
donors inhibit luciferase expression in a promoter-independent fashion. J Biol
Chem. 2003; 278(12):10232e8.
y Jia X, Cheng K, Mahato RI. Co-expression of vascular endothelial growth factor
and IL-1 receptor antagonist for improved human islet survival and function. Mol
Pharm. 2007; 4(2):199e207.
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at 120 and 180 days, while OA-resistant Strain 13 animals
demonstrated a signiﬁcant reduction in immunostaining. Enduring
IL-1b levels in Hartley animals appeared to coincide with histologic
onset of OA, and this aberrant expression may correlate to early
incidence of disease. Although ﬁndings suggested, but did not
conﬁrm, a cause-and-effect relationship between IL-1b expression
and OA, we demonstrated a window when targeted cytokine
reduction and/or blockade may identify such a connection and
point toward mechanistic components. As such, the primary aim of
this study was to minimize IL-1b-mediated signaling via RNAi-
based transcript reduction or receptor blockade and quantify
changes incurred on expression of mediators implicated in patho-
genesis. We accomplished these aims via independent adminis-
tration of a validated adeno-associated viral serotype 5 vector
(AAV5) containing a short hairpin (sh)RNA knockdown sequence19,
or an adenoviral (Ad) vector encoding for recombinant human IRAP
(hIRAP). These treatments were contrasted with opposite knees
receiving corresponding vector controls with the goal of deﬁning
the contribution of IL-1b to spontaneous OA. A secondary aim was
to challenge the efﬁcacy and potential therapeutic viability of the
AAV5 vector relative to saline-only injected control knees. Histo-
logic chondropathy and immunohistochemistry (IHC) ﬁndings
were compared to untreated guinea pigs.
Materials & methods
This study was performed according to the Guide for the Care
and Use of Laboratory Animals of the NIH; all procedures were
approved by the Institutional Laboratory Animal Care and Use
Committee at the host university. Male Hartley guinea pigs (Charles
River Laboratories, Wilmington, MA) were utilized in this study
(N ¼ 32) starting at 60 days of age. Animals were housed individ-
ually in solid bottom cages and allowed ad libitumwater and guinea
pig chow (Harlan Teklad 7006) until euthanasia. Body weight
(grams) at time of harvest was recorded.
Experimental design
AAV5 vectors allowed simultaneous expression of shRNA via
the U6 promoter and cytomegalovirus (CMV)-driven enhanced
green ﬂuorescent protein (GFP) expression. Plasmids containing
the IL-1b speciﬁc shRNA knockdown sequence or non-targeting
shRNA control sequence (Table IA) were used to produce tar-
geting knockdown vector (TV) and non-targeting control vector
(NTV), respectively, by the Viral Vector Core at Nationwide
Children’s Hospital19,20. Ad vectors contained coding regions for
CMV-driven ﬁreﬂy luciferase (Ad-Luc) or hIRAP (Ad-hIRAP) and
were propagated, as described12. Active protein production from
Ad vectors was conﬁrmed in vitro using bioluminescent lucif-
erase detection or ELISA analyses for hIRAP (R&D Systems,
Minneapolis, MN); results were positive for intended proteins,
only.
Animals were injected at 60 days of age (four treatment groups;
four animals/treatment group per collection date) and harvested at
either 120 or 180 days of age. Vectors were aseptically administered
into the medial aspect of the knee just distal to the femoral condyle
using a 1/2cc 28g insulin syringe (Becton Dickinson, Franklin Lakes,
NJ). Animals were assigned to one of two groups to investigate
reduction/blockade of IL-1b vs respective vector controls: TV or
NTV (11012 DNase resistant particles) were injected into opposite
knees (group 1); Ad-Luc or Ad-hIRAP (2  1011 infectious units
(IFUs)) were injected into opposite knees (group 2). Group 3
animals received TV or an equivalent volume of phosphate buffered
saline (PBS) in opposite knees to challenge the efﬁcacy of TV in theabsence of vector control. Group 4 animals did not receive injec-
tions in either knee to allow reference of the above treatment
groups to untreated controls. A total volume of 100 ml was
administered; dosages and ﬁnal injection volume were consistent
with peer-reviewed manuscripts19,20.
For groups 1e3, RNA was extracted from weight-bearing carti-
lage taken from the lateral femoral condyle and lateral tibial
plateau of opposite knees for gene expression analyses. DNA was
collected from patellar cartilage to quantify viral particle numbers.
The medial femoral condyle and medial tibial plateau were pro-
cessed for IHC and histology. Whole knee joints from group 4
animals were processed for IHC and histology.Quantiﬁcation of CMV copy number
DNA was isolated via the QIAamp DNA Mini kit (Qiagen,
Valencia, CA) according to manufacturer’s protocol. DNA quality
and concentration were determined using the BioMate 3 spec-
trophotometer (Thermo Fisher Scientiﬁc, Waltham, MA). Absolute
quantiﬁcation of initial CMV copy number per 1 mg starting DNA
was performed in triplicate using SYBR Green PCR Master Mix
(Applied Biosystems, Warrington, UK) and primers speciﬁc for the
CVM promoter (Table IB) on the ABI Prism 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA). A standard
curve ranging from 107 to 101 starting particles was prepared
using the TV plasmid. If ampliﬁcation was not detected, negative
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starting DNA.
Relative real-time (Q)RT-PCR
Total RNA was isolated via TRIzol (Invitrogen, Carlsbad, CA),
followed by DNase I treatment (Invitrogen, Carlsbad, CA), according
to manufacturer’s protocol. Complementary DNA was made using
Taqman Reverse Transcription Reagents (Applied Biosystems,
Foster City, CA) and relative qRT-PCR, complete with dissociation
curve,wasperformed in triplicate foreach transcript of interestusing
Power SYBR Green PCR Master Mix (Applied Biosystems, War-
rington, UK) and speciﬁc primers (Table IB) on the ABI Prism 7000.
18s ribosomal RNA andGlyceraldehyde 3-phosphate dehydrogenase
(GAPDH) were used as separate endogenous controls to which each
transcript was normalized. Results were consistent between
housekeeping genes; DCT values using GAPDH are represented. If
ampliﬁcation was not detected, reactions were repeated using
a higher starting amount of cDNA to conﬁrm negative ﬁndings. DCT
values for GFP transcripts in groups 1 and 3 at 120 and 180 dayswere
reported. Fold differences and subsequent percent gene expression
levels relative to designated control groups were calculated for each
transcript using the comparative cycle threshold (CT) (2DDCT)
method. For all groups, comparative CT values for each treatment
group were compared to opposite control knees.
Luciferase expression
Immediately prior to euthanasia, in vivo bioluminescent
imaging was performed to ensure luciferase activity in knees
receiving Ad-Luc. Group 2 animals at 120 and 180 days were
induced and maintained under general anesthesia using 2% iso-
ﬂurane and received an intra-peritoneal injection of D-luciferin
(Caliper Life Sciences, Hopkinton, MA) at a dose of 150 mg/kg.
Fifteen minutes post-injection, animals were placed in a cooled
charge-coupled device camera system (IVIS Imaging System-100;
Xenogen/Caliper Life Sciences, Alameda, CA) for data acquisition
according to recommendations21.
Joint processing & analyses
Knee joints were ﬁxed in 10% neutral buffered formalin and
prepared for histological analysis18,22e25. Parafﬁn sections (5 mm)
were taken from the center of the medial tibial plateau in each joint
and either stained with toluidine blue or subjected to IHC. Four
sections from each joint were examined using each scoring
technique.
IHC was performed on the Benchmark XT (Ventana, Tucson, AZ)
using the Ultraview Universal Red AP System and a rabbit poly-
clonal antibody for IL-1b (sc-7884; Santa Cruz Biotechnology, Santa
Cruz, CA) at a dilution of 1:800. Sections were counterstained with
hematoxylin. The percentage of chondrocytes staining positive for
IL-1b were assessed by two independent, blinded reviewers (KSS/
GN) and assigned a total IHC (based on the percentage and intensity
of chondrocytes staining positive for IL-1b) ranging from 0e818.
Intra- and inter-observer variability was negligible (within one
numeric score in all cases).
Two independent, blinded observers (KSS/ALB) performed
histological grading of serial coronal sections of each knee, using
adapted Mankin criteria based upon species-speciﬁc features of
OA24,25. Chondropathy was scored for the medial femorae and tibial
plateaus, providing a total possible medial joint index ranging from
0e28. Intra- and inter-observer variability was negligible (within
one numeric score in all cases).Statistical analyses
Individual samples harvested from each animal were consid-
ered independent observations; for each gene or transcript of
interest, this resulted in four independent observations per treat-
ment group per harvest date. DCT values for each gene or transcript
of interest (triplicate values for each independent observation)
passed Gaussian distribution and homogeneous variance using the
KolmogoroveSmirnov normality test. Statistical differences were
not detected between animals within the same treatment group
and harvest date. Weight, viral particle numbers, and relative
percent expression qRT-PCR data (directly converted from fold
changes) were expressed as mean  95% conﬁdence interval and
analyzed by one-way ANOVA followed by pairwise comparisons
using Tukey 95% conﬁdence intervals. Total indices for OA and IHC
(median and range provided) were analyzed using the one-way
ANOVA, KruskaleWallis test, followed by Dunn’s Multiple
Comparison post-hoc test18. All analyses were performed using the
Minitab statistical software program (State College, PA) with
a statistical signiﬁcance of P < 0.05. Throughout the manuscript,
indicated “increases” and “decreases” in transcript expression refer
to signiﬁcant statistical differences in presented data.
Results
Successful transduction of patellar cartilage by TV and NTV was
conﬁrmed via detectable ampliﬁcation of the CMV promoter at 120
and 180 days [Fig. 1(A)]; signiﬁcant statistical differences between
days 120 and 180 or between groups 1 and 3 were not present. The
CMV promoter was not detected in patellar cartilage harvested
from group 2 animals injected with either Ad vector.
GFP expression was detected via qRT-PCR in knees receiving
either TV or NTV. Signiﬁcant statistical differences in DCT values
were not present between days 120 and 180 or between groups 1
and 3 [Fig. 1(B)].
Luciferase expression in knees receiving Ad-Luc displayed
positive bioluminescence immediately prior to collection, indi-
cating successful transduction in joint tissue throughout the
duration of the study [Fig. 1(C)]. Neither luciferase nor hIRAP
transcripts was detected in cartilage via qRT-PCR, conﬁrming that,
along with lack of detection of CMV promoter, Ad-Luc and Ad-IRAP
vectors transduced joint structures other than the examined
cartilage.
IL-1b reduction/blockade vs respective vector controls
TV relative to NTV, and Ad-hIRAP relative to Ad-Luc, demon-
strated decreases in IL-1b expression in cartilage at 120 days
[Table II(A)]. IL-1b was below detection limits collected from both
groups at 180 days. In general, TV and Ad-hIRAP decreased
expression of tumor necrosis factor-a (TNF-a), IL-8, and interferon-
g (IFN-g) relative to respective vector controls [Table II(B)]. TNF-
a and IL-8 were decreased by TV compared to NTV at both harvest
ages. Signiﬁcant statistical differences in IFN-gwere not detected at
120 or 180 days. TNF-awas increased by Ad-hIRAP vs Ad-Luc at 120
days. This expression, however, was decreased relative to Ad-Luc by
180 days, revealing a signiﬁcant statistical difference in Ad-hIRAP
treated knees between 120 and 180 days (Supplemental Table I).
IL-8 and IFN-g were decreased by Ad-hIRAP at both collection
times. Overall, anabolic transforming growth factor-b1 (TGF-b1)
was increased by TV and Ad-hIRAP relative to vector controls at 120
days [Table II(C)]. This increase in group 1 continued at 180 days;
however, TGF-b was decreased in group 2 at this time. Catabolic
collagenase III/matrix metalloproteinase 13 (MMP13) was
decreased by either method used to manipulate IL-1b at 120 days
Fig. 1. In vivo detection of the CMV promoter (A) in 1 mg starting DNA and expression of reporter genes for AAV5 (B) and adenoviral (Ad) vectors (C) were conﬁrmed using PCR, qRT-
PCR, and Xenogen IVIS System, respectively. DNA containing the CMV promoter was not detected (ND) in patellar cartilage collected from group 2 Ad-injected animals at either 120
or 180 days of age. A signiﬁcant difference for this promoter between groups 1 and 3 was not present at either harvest date. Statistical differences in GFP expression were not noted
in cartilage at 120 or 180 days of age in groups 1 and 3, as determined using one-way ANOVA followed by pairwise comparisons using Tukey’s 95% conﬁdence intervals. Luciferase
(Luc) expression was detected in all Ad-Luc injected knees immediately prior to harvest on both collection ages (C). TV ¼ AAV5-shRNA-TV; NTV ¼ AAV5-shRNA-NTV; Ad-Luc, vector
containing a CMV-driven coding region for ﬁreﬂy luciferase (Luc); Ad-hIRAP, vector containing a CMV-driven coding region for hIRAP.
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relative to NTV persisted, while Ad-hIRAP increased expression
relative to Ad-Luc.
Reduction of IL-1b by shRNA-TV relative to PBS control (group 3)
To stringently evaluate efﬁcacy of novel TV in the context of
primary OA, this vector was compared to opposite control knees
receiving PBS, only (group 3). Successful in vivo transduction of
patellar cartilage by TV was conﬁrmed via detectable, and
similar, ampliﬁcation of the CMV promoter at both 120 and
180 days [Fig. 1(A)] and discernible, and comparable, DCT values
for GFP between days 120 and 180 [Fig. 1(B)]. At 120 and
180 days, the IL-1b transcript was decreased relative to PBS
control [Table III(A)]. At 120 days, TNF-a, IL-8, and IFN-g were
increased by TV relative to PBS [Table III(B)]. TNF-a and IL-8,
however, were decreased by 180 days, while IFN-g remainedTable II
Relative percent expression (mean 95% conﬁdence intervals) of (A) IL-1b, (B) inﬂammat
vector treated knees vs vector control knees (groups 1 and 2) at speciﬁed ages
Group 1
NTV TV P value
A. IL-1b
120 days 100.0 (84.1, 115.9) 5.5 (3.9, 7.1) <0.001
180 days ND ND NA
B. TNF-a
120 days 100.0 (80.9, 119.1) 15.3 (7.3, 23.3) <0.001
180 days 100.0 (87.3, 112.7) 23.8 (7.9, 39.7) <0.001
IL-8
120 days 100.0 (84.1, 115.9) ND <0.001
180 days 100.0 (85.7, 114.3) 21.0 (5.1, 36.9) <0.001
IFN-g
120 days 100.0 (94.1, 105.9) 120.0 (65.8, 239.1) >0.05
180 days 100.0 (86.8, 113.4) 75.0 (44.3, 194.3) >0.05
C. TGF-b1
120 days 100.0 (92.0, 108.0) 643.0 (324.8, 961.2) <0.001
180 days 100.0 (92.4, 108.0) 412.6 (223.9, 1,049.0) <0.001
D. MMP13
120 days 100.0 (94.1, 105.9) ND <0.001
180 days 100.0 (85.6, 114.3) ND <0.001
ND ¼ not detected; NA ¼ not applicable.increased. TGF-b1 was increased by TV relative to PBS at 120 and
180 days, with impressive expression found at the latter time
point [Table III(C)]. MMP13 was decreased by TV at both harvest
dates [Table III(D)].
Comparison of Ad-Luc and Ad-hIRAP (group 2) to PBS control knees
(group 3)
Comparison of Ad-Luc or Ad-hIRAP vs PBSwas performed across
animals. At 120 days, Ad-Luc-treated knees demonstrated
increased IL-1b relative to PBS control knees [Table IV(A)]. IL-1b
was below detection in Ad-hIRAP-treated knees at either time
point; although detected at 120 days, IL-1b was not present in Ad-
Luc treated knees at 180 days. All inﬂammatory cytokines of
interest were increased by Ad-Luc and Ad-hIRAP relative to PBS
control knees at 120 days [Table IV(B)]. TNF-a was increased
compared to PBS exposed cartilage at 180 days and, in Ad-Lucory cytokines of interest, and (C) anabolic and (D) catabolic agents in cartilage of viral
Group 2
Ad-Luc Ad-hIRAP P value
120 days 100.0 (90.5, 109.5) ND <0.001
180 days ND ND NA
120 days 100.0 (82.5, 117.5) 720.6 (584.1, 1,357.0) <0.001
180 days 100.0 (85.7, 114.3) 33.0 (14.7, 80.7) 0.01
120 days 100.0 (94.5, 105.4) 35.4 (15.5, 55.3) <0.001
180 days 100.0 (83.7, 117.4) 32.2 (17.6, 51.9) <0.001
120 days 100.0 (90.4, 109.5) 5 (1.8, 8.2) <0.001
180 days 100.0 (87.2, 113.7) 42.1 (18.2, 65.9) <0.001
120 days 100.0 (90.5, 109.5) 873.2 (236.7, 1,510.0) <0.001
180 days 100.0 (84.1, 115.9) 32.5 (6.8, 64.3) 0.008
120 days 100.0 (93.4, 107.5) ND <0.001
180 days 100.0 (87.3, 112.7) 200.0 (144.3, 255.7) <0.001
Table III
Relative percent expression (mean  95% conﬁdence intervals) of (A) IL-1b, (B)
inﬂammatory cytokines of interest, and (C) anabolic and (D) catabolic agents in
cartilage of AAV5 vector-exposed guinea pigs compared to PBS-treated knees
(group 3) at speciﬁed ages
Group 3
PBS TV P value
A. IL-1b
120 days 100.0 (87.2, 112.7) 64.8 (45.7, 82.9) 0.03
180 days 100.0 (88.8, 111.1) 42.0 (18.1, 65.8) <0.001
B. TNF-a
120 days 100.0 (93.6, 106.4) 266.0 (126.9, 425.1) <0.001
180 days 100.0 (92.0, 108.0) 25.0 (4.8, 64.7) 0.005
IL-8
120 days 100.0 (87.2, 112.7) 179.0 (123.3, 234.7) <0.001
180 days 100.0 (88.6, 111.4) 70.0 (49.3, 90.7) 0.04
IFN-g
120 days 100.0 (82.7, 117.2) 608.0 (448.9, 767.1) <0.001
180 days 100.0 (90.6, 110.4) 1,087.0 (768.8, 1,405.0) <0.001
C. TGF-b1
120 days 100.0 (93.6, 106.4) 156.0 (116.4, 235.6) 0.009
180 days 100.0 (92.0, 108.0) 542.7 (304.0, 781.4) <0.001
D. MMP13
120 days 100.0 (87.3, 112.7) 30.0 (16.1, 53.8) 0.003
180 days 100.0 (88.6, 111.1) 10.0 (2.0, 17.9) <0.001
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time point [Table IV(B); Supplemental Table I]. IL-8 and IFN-gwere
decreased at 180 days relative to 120 days within knees exposed to
Ad vectors (Supplemental Table I). At 180 days, only Ad-Luc
demonstrated an increase in IL-8 relative to PBS-exposed carti-
lage and both IL-8 and INF-g were decreased in Ad-hIRAP treated
cartilage relative to PBS knees by this harvest date. At 120 days,
TGF-b1 was increased in cartilage treated with either Ad vector
relative to PBS treated knees [Table IV(C)]. By 180 days, however,
transcript expression was decreased in Ad-hIRAP treated knees.
MMP13 was decreased by both Ad vectors relative to PBS control
cartilage at 120 days, but increased at the latter harvest age
[Table IV(D)].IHC and histology
A ﬁnal set of animals (group 4) did not receive injections in
either knee to allow reference of IHC and chondropathy fromTable IV
Relative percent expression (mean  95% conﬁdence intervals) of (A) IL-1b, (C) inﬂamm
speciﬁed ages in Ad vector treated animals vs PBS-treated knees
PBS Ad-Luc P value
A. IL-1b
120 days 100.0 (87.2, 112.7) 362.0 (123.3, 600.7) <0.001
180 days 100.0 (88.8, 111.1) ND <0.001
B. TNF-a
120 days 100.0 (93.6, 106.4) 1,420.0 (1,261.0, 1,579.0) <0.001
180 days 100.0 (92.0, 108.0) 4,440.0 (1,258.0, 7,622.0) <0.001
IL-8
120 days 100.0 (87.3, 113.1) 1,389.0 (672.9, 2,105.0) <0.001
180 days 100.0 (88.8, 111.1) 173.0 (119.3, 252.6) <0.009
IFN-g
120 days 100.0 (90.4, 109.5) 3,335.0 (1,744.0, 4,926.0) <0.001
180 days 100.0 (87.7, 112.7) 84.0 (52.1, 115.8) >0.05
C. TGF-b1
120 days 100.0 (93.6, 106.3) 251.0 (127.8, 394.2) <0.001
180 days 100.0 (84.1, 115.9) 222.0 (174.3, 269.7) <0.001
D MMP13
120 days 100.0 (87.3, 112.7) 50.0 (10.2, 79.8) 0.005
180 days 100.0 (89.6, 111.1) 179.0 (139.2, 218.8) <0.001
ND ¼ not detected.treatment groups to untreated controls. IHC to detect IL-1b was
performed and graded to corroborate qRT-PCR ﬁndings. Scores for
IL-1b at the protein level reﬂected qRT-PCR data, where IHC indices
were lower in groups 1, 2, and 3 relative to untreated group 4 at
both 120 and 180 days [Fig. 2(A, B)]. Total OA indices for the medial
joint compartments increased from 120 to 180 days, similar to that
previously reported18,22e25 [Fig. 2(B, C)]. Signiﬁcant statistical
differences in OA indices were not present among treatment groups
within speciﬁed harvest dates. Signiﬁcant statistical differences in
weight were not detected among the treatment groups at either
120 or 180 days [Fig. 2(D)].
Discussion
The goals of our study were to demonstrate effective intra-
articular vector transduction aimed at reducing IL-1b expression
and/or signaling in OA-prone cartilage, quantify ensuing chondro-
genic mediator proﬁles in articular cartilage, and provide compel-
ling molecular evidence for potential disease modiﬁcation. Both TV
and Ad-hIRAP were successful at decreasing IL-1b expression in
OA-prone cartilage at both the transcript and protein levels.
Notably, this IL-1b diminution directly affected several key players
implicated in joint degeneration. Relative to respective vector
controls, these anti-IL-1b treatments reduced TNF-a, IL-8, IFN-g,
and simultaneously increased anabolic TGF-b and decreased cata-
bolic MMP1326,27. Importantly, these same patterns were eluci-
dated when TV was compared to contralateral PBS-exposed
cartilage; these ﬁndings can be anticipated to allow a joint envi-
ronment less acquiescent to pathology. As such, our work supplied
conﬁrmation that treatments aimed at decreasing the effective
concentration of IL-1 and/or its signaling may hold merit for
amendment of disease-prone cartilage.
To date, intra-articular hIL-1Ra injections to treat symptomatic
knee OA in people found no statistical improvement over placebo at
1 month28 and trials with diacerein did not show clinical, radio-
graphic, or structure-modifying effects as anticipated29e31. Use of
recombinant proteins and/or pharmaceutical compounds is limited
not only by short half-lives and the requirement for repeat
administration, but uncharacterized innate and adaptive responses
to exogenous substances may also affect efﬁcacy, including inter-
nalization or down-regulation of receptors. Although we demon-
strated an ability to manipulate IL-1b signaling in cartilage such
that correlative expression changes in other mediators could beatory cytokines of interest, and (D) anabolic and (E) catabolic agents in cartilage at
PBS Ad-hIRAP P value
120 days 100.0 (87.2, 112.7) ND <0.001
180 days 100.0 (88.8, 111.1) ND <0.001
120 days 100.0 (93.6, 106.4) 2,181.0 (1,544.0, 2,817.0) <0.001
180 days 100.0 (92.0, 108.0) 1,465.0 (1,306.0, 1,624.0) <0.001
120 days 100.0 (87.3, 113.1) 492.0 (332.9, 651.1) <0.001
180 days 100.0 (88.8, 111.1) 55.8 (23.9, 87.6) 0.04
120 days 100.0 (90.4, 109.5) 166.8 (121.1, 222.4) <0.001
180 days 100.0 (87.7, 112.7) 35.3 (19.4, 51.2) 0.006
120 days 100.0 (93.6, 106.3) 2.1  105 (1.9  105, 2.5  105) <0.001
180 days 100.0 (84.1, 115.9) 39.6 (25.3, 53.9) 0.01
120 days 100.0 (87.3, 112.7) ND <0.001
180 days 100.0 (89.6, 111.1) 358.0 (198.9, 517.1) <0.001
Fig. 2. Median (range provided) IHC scoring (A) and OA grading (C), mean body weight (D), and representative photomicrographs (B) (100, ﬁnal magniﬁcation), of medial tibial
plateaus from treatment groups harvested at speciﬁed ages. Animals were injected with viral vectors (N ¼ 4 animals per treatment group per collection date) at 60 days of age and
harvested at either 120 or 180 days of age. At time of treatment, animals were assigned to one of two groups to investigate reduction or blockade, respectively, of IL-1b vs respective
vector controls: TV or NTV were injected into contralateral knees (group 1); Ad-Luc or Ad-hIRAP were injected into contralateral knees (group 2). A third set of animals (group 3)
received TV or PBS in contralateral knees to challenge the efﬁcacy of TV in the absence of vector control. A ﬁnal set of animals (group 4) did not receive injections in either knee to
allow reference of the above treatment groups to untreated controls. The percentage of chondrocytes staining positive for IL-1b were assigned a score of 0e5 and a scale of 1e3 was
used to gauge the intensity of immunostaining (total ranging from 0e8). Histological grading of serial coronal sections of the medial weight-bearing compartment of each knee was
performed using adapted Mankin criteria based upon characteristic features of OA in this species. The score for each structure ranged from 0 (normal) to 14 (severe structural
damage and complete loss of toluidine blue staining), providing a total chondropathy index ranging from 0e28. Data were analyzed using the ANOVA, KruskaleWallis test, followed
by Dunn’s multiple comparison post-hoc test. (Please see Fig. 1 for full description of abbreviations. yP < 0.05.)
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treatment. Additional workwould be required to determine if these
treatments would alter the progression and/or severity of OA in this
animal model at later dates. Of note, quantiﬁcation of hIRAP, type II
collagen, and aggrecan, as well as IL-1b signaling molecules and
additional cytokine isoforms, in the entire joint organ would
provide greater insight into global responses to the chosen thera-
pies. As sequencing and annotation of the guinea pig genome is still
underway, full-scale investigations remain limited without an
exhaustive list of available reagents. As such, it is plausible that
compensatory or supplanting biomechanical/molecular factors not
targeted in our work could have contributed to initial pathogenesis.
Residual IL-1b activity may have persisted from tissues other than
the examined cartilage and compensatory cytokines, including
IL-1a, could have superseded therapeutic advantages. In addition,
work has demonstrated persistent and robust reporter gene
expression via self-complementary (sc)AAV20, It is possible this
vector could achieve earlier gene expression and greater effec-
tiveness in the guinea pig model than single-stranded AAV; indeed,
scAAV vector encoding hIRAP has been validated for intra-articular
use32. Further, it may be necessary to combine interventional
therapies with IL-1b reduction to achieve a more effective
suppression of disease. Attempts to alter the effective concentra-
tion of IL-1b may be co-dependent on additional management e
such as reduction of loading e at critical time points during disease
development. Continued, and longer term, in vivo work is war-
ranted to investigate therapeutic modiﬁcations that would
compliment anti-IL-1b molecular therapy. Assessment of gait
improvements and/or reduction in joint pain may also detect
positive outcomes related to the suppression of inﬂammatory
mediators4. Our ﬁndings reinforce the credence that timely iden-
tiﬁcation of individuals at premature risk for OA, followed by
immediatemulti-modal treatment, is necessary to provide a setting
that is conducive to disease suppression.
One unique ﬁnding was that IL-1b transcript and protein
expression was reduced at 180 days in all animals that received
either anti-IL-1b vector, including untreated knees, when
compared to untreated group 4 animals. Interestingly, this is not
a new or unexpected observation. Beneﬁcial alterations in
untreated contralateral limbs or regional joints has been demon-
strated under a number of experimental conditions33e36, including
animal models of rheumatoid arthritis37,38. Two explanations for
this include translocation of vector to opposite limbs or migration
of transduced or immune-modulated cells to outside the joint. In
particular, migration of immunotolerant dendritic cells stimulated
by anti-IL-1b therapy has been described37 and additional
uncharacterized mechanisms of local or systemic cytokine
suppression may also exist. Given the positive feedback loop that
this pro-inﬂammatory molecule exerts on itself, as well as the
synergism it has with other cytokines, it is also possible that even
slight reduction/blockade of IL-1b may have far-reaching effects.
Interestingly, diacerein is reported to have a carryover effect,
providing more pain relief than placebo or non-steroidal anti-
inﬂammatory drug (NSAID) for several weeks after treatment
cessation39. Although additional corroboration is needed, these
results could represent one of our more important ﬁndings.
Optimal viral vectors for intra-articular gene delivery for RNAi or
protein production must be capable of efﬁcient and sustained
transgene expression within a reasonable vector particle dose. Our
ﬁndings indicated that both AAV and Ad vectors are viable tools
capable of these aims. Speciﬁcally, our results veriﬁed that AAV5
transduced weight-bearing and non-weight-bearing cartilage,
which is consistent with previous work20,40, and are effective
vehicles to induce RNAi machinery in situ41,42. Importantly, CMV
copy numbers and GFP transcript expression were not signiﬁcantlydifferent between 120 and 180 days, indicating persistent expres-
sion over multiple months. As expected, evidence of transduction
of articular cartilage by Ad was not demonstrated; however, lucif-
erase expression from other articular structures was conﬁrmed for
at least 120 days in our study, which is longer than the 2e3 week
period of transgene expression typically purported for Ad in most
tissues of interest43.
Adverse cellular responses must be nominal in the presence of
viral vectors and these delivery vehicles must not detrimentally
inﬂuence or unseat the intended therapy. AAV vectors have been
associated with minimal toxicity and immune responses43e45. In
the current work, TNF-a, IL-8, and IFN-gwere statistically increased
by TV relative to paired PBS-treated knees 60 days after injection.
These relative increases in TNF-a and IL-8 expression levels induced
by AAV vectors, however, appeared to be transitory43 and were
statistically decreased 120 days post-injection. A persistent
increase in IFN-g was present in both TV and NTV knees, which is
most likely related to vector use and not RNAi mechanisms. Our
results support other peer-reviewed studies, which demonstrated
cell-mediated immune responses to AAV capsid antigens46,47 and
persistent, serotype-speciﬁc IFN-g responses. Further, in vitro IFN-g
release assays have shown differences in species susceptibility to
immunogens or mitogens, emphasizing the importance to scruti-
nize immune responses to AAV vectors in the context of individual
animal models48 and tissue types. Continued work is necessary to
examine the inﬂuence of innate and adaptive immune responses to
AAV5 vectors on our results in the guinea pig, with emphasis on the
signiﬁcance of IFN-g in cartilage.
Ad vector particles elicit strong immune responses, often in
a dose-dependent manner, and systemic delivery has resulted in
rapid physiological responses that include activation of intrinsic
defense mechanisms, induction of inﬂammation, transient liver
toxicity, and thrombocytopenia49. These vectors activate innate
immunity through toll-like receptor (TLR)-dependent and TLR-
independent pathways, causing an upregulation of type I IFNs
and inﬂammatory cytokines50. Adaptive responses against Ad may
be directed against the capsid, double-stranded DNA genome, viral
proteins expressed from the vector backbone, or incorporated
transgenes43. In comparison to PBS-injected knees, Ad vector-
exposed cartilage had a signiﬁcant increase in inﬂammatory cyto-
kine expression, speciﬁcally TNF-a, IL-8, and IFN-g, especially at
120 days. Given the adaptive immune response anticipated in
response to Ad, as well as the reversal of the potentially beneﬁcial
alterations in TGF-b and MMP13 expression between 120 and 180
days, it would be interesting to determine if there was evidence at
the latter time point of host response to foreign antigens. Addi-
tional studies are needed to investigate immune responses speciﬁc
to the joint environment and to ascertain if viral vector use usurped
or prejudiced the beneﬁcial effects of the investigated therapies.
There are theoretical advantages to using RNAi vs standard gene
delivery of a therapeutic product. First, as selected shRNA
sequences are reliably and constitutively transcribed from poly-
merase III promoters and efﬁciently processed by the RNA-induced
silencing complex, RNAi does not face hurdles related to proper
protein production. Second, the development of techniques to
deliver long-lasting siRNAs to cells in the absence of a delivery
vehicle or viral vector may eliminate negative consequences asso-
ciated with vector/DNA administration. Finally, although it is
unknown the extent towhich dsRNA stimulates induction of innate
cellular immune responses, this obstaclemay be easier to overcome
than conventional gene delivery due to the ability to identify highly
potent RNAi sequences. Efﬁcient small interfering RNA molecules
decrease the likelihood of off-target effects, decrease the concen-
tration of dsRNA molecules required, and may be better able to
evade host responses. In the context of the current study,
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a reduced IL-1b signaling at the transcript level compared to
receptor antagonism of the IL-1 type I receptor by hIRAP. Further
effort is required to determine which method pursued in this study
may be more effective.
In summary, this work demonstrated that a reduction in IL-1b
signaling by shRNA-mediated RNAi or receptor blockade by hIRAP
was achieved in the Hartley guinea pig model of OA. Importantly,
this manipulation was demonstrated over a 60-day period.
Reducing the effective concentration of IL-1b decreased expression
of three inﬂammatory mediators and one catabolic agent, while
simultaneously increasing the number of anabolic TGF-b tran-
scripts, providing biological evidence that IL-1b serves an impor-
tant role in primary OA.
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